Pakistan Journal of Pharmaceutical Sciences

Abstract: Neonatal septicemia seriously threatening the lives of pediatric patients and currently facing certain challenges in clinical treatment. This study analyzed the effectiveness of cefotaxime sodium combined with penicillin in the treatment of neonatal sepsis and the effect on immunity levels. 101 septic neonates from the Affiliated People’s Hospital of Ningbo University between October 2020 and December 2023 were divided into CS and CP groups; both groups were treated with cefotaxime sodium and penicillin was added to CP group. The primary assessment was the clinical efficacy, inflammatory and immune indices of both groups. Secondary outcomes included symptom improvement time, serum procalcitonin levels and white blood cell (WBC) counts, recurrence rate, complication status and adverse reaction incidences. After treatment, the indices of both groups were compared for any significant difference with pre-treatment. The clinical efficacy, immunity indices, symptom improvement of CP group were significantly higher than CS group and inflammatory indices, serum procalcitonin levels and WBC counts, complication conditions and adverse reaction incidences were significantly lower than the CS group (P<0.05). No obvious differences of recurrence rate among both groups (P>0.05) were found. This combined therapy has a remarkable curative effect, which is worthy of popularization and use in the clinic.